peter attia on semaglutide A new study from UC San Diego offers early clinical evidence that semaglutide, a widely used GLP-1 receptor agonist, may slow biological aging. In a randomized, placebo-controlled trial, researchers observed a 9% dr peter attia semaglutide MD:

Besides lowering blood glucose, Semaglutide decreases body weight and systolic blood pressure [7], but it increases the risk of nausea, vomiting and diarrhoea [7, 8]

RegenCen provides physician-guided testosterone therapy designed to restore levels to a healthy physiologic range while monitoring long-term health and treatment response

* Disclaimer - Based on a comparison of studies measuring weight loss with similar BMI measurements over a 8 week period for active Noom Med patients prescribed a GLP-1 medication and active Noom Healthy Weight customers not taking medication

The peptide increases superoxide dismutase (SOD) activity by delivering copper, which serves as a cofactor for this important antioxidant enzyme